ArticleBiochemical genetics2026
Expression of Transforming Growth Factor Beta 1 in Lung Adenocarcinoma and Its Relationship with Circulating Tumour Cells.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the relationship between the expression of transforming growth factor beta 1 (TGF-β1), epithelial-mesenchymal transition (EMT)-related proteins, circulating tumour cells (CTCs) positivity rate and tumour differentiation degree in lung adenocarcinoma. A prospective study was conducted, including 78 patients with lung adenocarcinoma who underwent surgical resection at our hospital between March 2021 and December 2021. Clinical data, lung adenocarcinoma and adjacent tissues were collected. Western blot, immunohistochemistry and RT-PCR were used to detect the expression of TGF-β1, EMT-related proteins (E-cadherin, vimentin) and mRNA in lung adenocarcinoma. Peripheral blood for CTC analysis was collected within 1 week before surgical resection. Pearson correlation analysis was employed to assess the relationship between TGF-β1, EMT and CTCs. There was a significant correlation between the positive rate of CTCs and the degree of tumour differentiation in patients with lung adenocarcinoma (P < 0.05). The expression of TGF-β1 increased significantly as the degree of differentiation decreased (P < 0.05). It was positively correlated with vimentin expression and negatively correlated with E-cadherin expression (P < 0.05). High expression of TGF-β1 in lung adenocarcinoma promotes EMT and the occurrence of CTCs and is associated with the degree of tumour differentiation.
Indexed as
Identifiers
42417912What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.